This product candidate targets the BJI market reaching 1.6 Bn€ in 2016.
This product candidate is currently under preclinical development. Several in vivo proof-of-concepts in rodents have been successfully obtained.
The polymeric hydrogel contains both daptomycin-loaded SOLUDOTS and free daptomycin. This composition provides a 3-step release allowing immediate, intermediate and prolonged release of the antibiotic from a single formulation.
1 : Daptomycin release from the gel
2 : Daptomycin release from SOLUDOTS, then from the gel
3 : SOLUDOTS release from the gel, then daptomycin from SOLUDOTS
This product candidate is being developed in collaboration with ATLANGRAM, a preclinical Contract Research Organisation specializing in efficacy testing of antimicrobials